Chunhe Pharmaceutical: CDE approves VG081821 for conducting Phase II clinical trials for the treatment of NASH/MASH.

On March 14, Zhejiang Chunhe Pharmaceutical Technology Co., Ltd. announced that its independently developed innovative drug VG081821 had made a breakthrough in the field of clinical development. The China National Medical Products Administration Drug Evaluation Center officially approved its clinical trial application for the second indication of non-alcoholic fatty liver disease.